Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV–Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015

Robert S. Rosenson, MD; Lisandro D. Colantonio, MD, PhD; Greer A. Burkholder, MD, MSPH; Ligong Chen, PhD, MS; Paul Muntner, PhD

Background—HIV is associated with an increased risk for atherosclerotic cardiovascular disease, which may result in many people living with HIV taking a statin. Some statins are contraindicated with certain antiretroviral therapies (ART) and other medications commonly used by HIV-infected patients.

Methods and Results—We analyzed trends in the use of statins, including contraindicated statins, between 2007 and 2015 among HIV-infected patients aged ≥19 years taking ART who had employer-sponsored or Medicare supplemental health insurance in the Marketscan database (n=186 420). Statin use was identified using pharmacy claims. Contraindicated statin use was defined by a pharmacy claim for HIV protease inhibitors, cobicistat, hepatitis C protease inhibitors, anti-infectives, calcium channel blockers, amiodarone, gemfibrozil, or nefazodone followed by a fill for a contraindicated statin type and dosage within 90 days. The percentage of beneficiaries with HIV taking a statin remained unchanged between 2007 (24.6%) and 2015 (24.7%). Among those taking a statin, the percentage taking a contraindicated statin declined from 16.3% in 2007 to 9.0% in 2014 and then increased to 9.8% in 2015. The proportion of contraindicated statin fills attributable to HIV protease inhibitors declined from 63.9% in 2007 to 51.0% in 2015, while those attributable to cobicistat increased from 0% before 2012 to 20.6% in 2015.

Conclusions—Changes in ART regimens resulted in a decline in contraindicated statin use from 2007 to 2014, but this favorable trend was attenuated in 2015 because of increased use of cobicistat-containing ART regimens. (J Am Heart Assoc. 2018;7: e010345. DOI: 10.1161/JAHA.118.010345)

Key Words: antiretroviral medications • cobicistat • drug interactions • HIV • hydroxymethylglutaryl-CoA reductase inhibitors • protease inhibitors

The use of antiretroviral therapies (ART) has resulted in a decline in opportunistic infections and increased life expectancy among people living with HIV.1 As a result, adults with HIV are developing chronic illnesses associated with older age.2,3 Cardiovascular disease (CVD) has emerged as a major cause of morbidity and mortality in people living with HIV.3–5

Statin therapy is a mainstay of atherosclerotic CVD prevention.6,7 The aging of people living with HIV and the high risk for CVD in this population may have resulted in an increased use of statin therapy in this population. Some statin types and dosages are contraindicated with medications commonly used to treat people living with HIV as they increase the risk for statin-related adverse events, including muscle problems and acute kidney injury.8,9 The risk for contraindicated statin use among adults with HIV may have changed over the past decade because of modifications in ART regimens.10

The main aim of the current study was to analyze trends in the use of statins and contraindicated statin use among adults living with HIV who were treated with ART between 2007 and 2015. As a secondary aim, we identified factors associated with contraindicated statin use among adults with HIV in 2015. To accomplish these aims, we conducted...
Clinical Perspective
What Is New?
- Contraindicated statin use in people living with HIV have declined between 2007 and 2014 because of less frequent prescriptions for HIV protease inhibitors.
- The decline in the use of contraindicated statins has diminished in the most recent years because of increasing prescriptions for antiretroviral regimens containing cobicistat.

What Are the Clinical Implications?
- There is a need for increased awareness of statin drug interactions in people living with HIV to minimize avoidable adverse events.

Methods
Study Population
The Marketscan database contains administrative data from individuals enrolled in various employer-sponsored health-care plans and Medicare supplemental plans. We identified beneficiaries in the Marketscan database who had continuous inpatient, outpatient, and pharmacy insurance coverage for at least 1 full calendar year (ie, from January 1 through December 31) between 2007 and 2015 (hereinafter defined as the “assessment year”). We also required beneficiaries to have continuous inpatient, outpatient, and pharmacy insurance coverage from January 1 through December 31 of the year preceding the assessment year (hereinafter defined as the “baseline year”) to identify baseline characteristics. We further restricted the analysis to beneficiaries who lived in the United States for the entire baseline and assessment years, were aged ≥19 years on January 1 of the assessment year and met the definition for HIV infection during the baseline year. HIV infection was defined by (1) ≥1 hospitalization with an International Classification of Diseases, Ninth Revision (ICD-9) code of 042.x-044.x or V08 in any discharge diagnosis position with ≥1 pharmacy claim for ART or (2) ≥2 pharmacy claims for ART on separate days. Table S1 shows the application of inclusion and exclusion criteria to identify the study population for the current analysis. The current analysis was approved by the Institutional Review Board at the University of Alabama at Birmingham, which waived the requirement to obtain informed consent. The Marketscan database used in the current study is available from Truven Health Analytics. Other study information is available from the corresponding author.

Beneficiary Characteristics
Beneficiary characteristics analyzed as part of the current analysis included age on January 1 of the assessment year, sex, and region of residence defined using Marketscan beneficiary data. We used claims in the baseline year to determine comorbidities including a history of coronary heart disease (CHD), hypertension, diabetes mellitus, stroke, chronic kidney disease, and liver disease (Table S2).

Use of Statins, ART, and Other Medications With Potential Contraindication With Statins
Use of statins, ART, and other medications with potential contraindications with statins was determined using pharmacy claims during the assessment year. Statins analyzed as part of the current study included atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. ART included nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors, cobicistat, and integrase inhibitors. As described below, other medications with potential contraindications with statins analyzed as part of the current study included nefazodone, gemfibrozil, amiodarone, calcium channel blockers, antifungal medications, antibiotics, and hepatitis C virus protease inhibitors.

Contraindicated statin use was defined by a pharmacy fill for a statin type and dosage which should not be used because of an increased risk for statin-related adverse events based on the medications filled in the preceding 90 days. Specific statin type and dosages which should not be used by individuals taking HIV protease inhibitors, cobicistat, hepatitis C protease inhibitors, antibiotics, antifungal medications, calcium channel blockers, amiodarone, gemfibrozil, and nefazodone are shown in Table S3. These contraindications were defined in accordance with the guidelines for the management of adults living with HIV from the National Library of Medicine, National Institutes of Health.11

Statistical Analysis
The analyses described below were conducted for each calendar year between 2007 and 2015, separately. We calculated baseline characteristics of beneficiaries included in the current analysis and the proportion who were taking ART and other medications with potential statin contraindications during the assessment year. We also calculated the
proportion of beneficiaries taking a statin during the assessment year, overall and by statin type. Among beneficiaries taking a statin, we calculated the proportion taking ART and other medications with a potential statin contraindication. We also calculated the proportion of beneficiaries with contraindicated statin use. Using all contraindicated statin fills, we calculated the proportion attributable to nefazodone, gemfibrozil, amiodarone, calcium channel blockers, antifungal medications, antibiotics, hepatitis C virus protease inhibitors, cobicistat, and HIV protease inhibitors. We also calculated the proportion of all contraindicated statin fills by statin type and dosage.

We used Poisson regression models with robust variance estimators as described by Chen et al to calculate risk ratios and 95% confidence intervals for filling a contraindicated statin during the assessment year associated with calendar year and beneficiary characteristics. Characteristics that were investigated included age, sex, region of residence, and history of CHD, hypertension, diabetes mellitus, stroke, chronic kidney disease, and liver disease. An unadjusted model was conducted as was a model including all factors investigated simultaneously. All analyses were conducted using SAS v9.4 (SAS Institute Inc, Cary, NC).

Results

Characteristics of Beneficiaries With HIV

A total of 186,420 beneficiaries with HIV met the inclusion criteria for the current analysis. The percentage of beneficiaries with HIV who were aged ≥60 years increased from 9.4% in 2007 to 15.7% in 2015 (Table 1). In each calendar year, >80% of beneficiaries were male and between 42% and 52% resided in the South region of the United States. Also, there was a progressive increase in the prevalence of CHD, hypertension, diabetes mellitus, chronic kidney disease, and liver disease between 2007 and 2015.

Between 2007 and 2015, there was a progressive decline in the proportion of beneficiaries taking HIV protease inhibitors from 50.8% in 2007 to 25.5% in 2015 and fusion inhibitors from 2.2% to 0.1% (Table 2, top panel). The use of cobicistat increased from 0% before 2012 to 15.7% in 2015, while the use of integrase inhibitors increased from 0% before 2012 to 15.7% in 2015.

Table 1. Baseline Characteristics of Beneficiaries With HIV Included in the Current Analysis

|                | 2007 (n=9928) | 2008 (n=11,713) | 2009 (n=19,868) | 2010 (n=21,084) | 2011 (n=24,781) | 2012 (n=28,810) | 2013 (n=24,892) | 2014 (n=24,225) | 2015 (n=21,825) |
|----------------|--------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| **Age**       |              |                |                |                |                |                |                |                |                |
| <50 y         | 60.1         | 58.0           | 58.9           | 57.1           | 54.8           | 51.8           | 48.9           | 47.9           | 47.3           |
| 50 to 59 y    | 30.5         | 31.6           | 31.1           | 32.1           | 33.4           | 34.8           | 36.0           | 37.0           | 37.1           |
| ≥60 y         | 9.4          | 10.4           | 10.0           | 10.8           | 11.8           | 13.4           | 15.1           | 15.2           | 15.7           |
| **Male**      | 84.8         | 84.6           | 84.9           | 84.6           | 85.0           | 84.3           | 84.4           | 83.3           | 83.2           |
| **Region**    |              |                |                |                |                |                |                |                |                |
| Northeast     | 12.2         | 10.2           | 12.1           | 16.4           | 15.9           | 18.2           | 18.4           | 21.2           | 20.7           |
| North Central | 13.5         | 13.4           | 15.4           | 16.7           | 15.0           | 14.4           | 13.0           | 13.4           | 12.8           |
| South         | 51.8         | 50.3           | 47.0           | 42.3           | 44.0           | 43.8           | 42.4           | 44.8           | 47.2           |
| West          | 22.3         | 25.7           | 24.1           | 24.4           | 24.2           | 22.7           | 25.4           | 19.3           | 19.2           |
| Unknown       | 0.3          | 0.3            | 1.4            | 0.2            | 0.8            | 0.8            | 0.8            | 1.3            | 0.1            |
| **Comorbidities** |         |                |                |                |                |                |                |                |                |
| Coronary heart disease | 3.2  | 3.5            | 3.1            | 3.7            | 3.8            | 3.8            | 3.9            | 3.9            | 3.9            |
| Hypertension  | 30.6         | 32.1           | 31.2           | 32.1           | 33.6           | 34.5           | 35.1           | 35.4           | 35.7           |
| Diabetes mellitus | 3.4  | 4.0            | 4.2            | 4.7            | 5.1            | 5.4            | 5.6            | 6.0            | 6.7            |
| Stroke        | 0.4          | 0.5            | 0.4            | 0.5            | 0.5            | 0.5            | 0.5            | 0.5            | 0.6            |
| Chronic kidney disease | 2.8  | 3.5            | 3.3            | 3.8            | 4.1            | 4.4            | 5.0            | 5.2            | 5.9            |
| Liver disease | 2.9          | 3.4            | 3.7            | 4.2            | 4.3            | 4.3            | 4.3            | 4.5            | 4.9            |

Numbers in the table represent percentages.
2007 to 36.2% in 2015. In each year, the most commonly used non-ART medications with potential contraindications with statins were calcium channel blockers, antifungal medications, and antibiotics (Table 2, bottom panel).

### Use of Statin Therapy

Statin use remained within 2 percentage points between 2007 and 2015 (Table 3). Atorvastatin was the statin most commonly used among beneficiaries with HIV during this time period, followed by pravastatin and rosuvastatin. Table 4 shows the use of ART and other medications with potential contraindications with statins among beneficiaries with HIV taking statin therapy. Between 2007 and 2015, the use of HIV protease inhibitors and fusion inhibitors decreased while the use of cobicistat and integrase inhibitors increased among beneficiaries with HIV taking statin therapy. Calcium channel blockers, antifungal medications, gemfibrozil, and antibiotics

### Table 2. Use of ART and Other Medications With Potential Contraindications With Statins Among Beneficiaries With HIV

| Year | Nucleoside reverse transcriptase inhibitors | Non-nucleoside reverse transcriptase inhibitors | HIV protease inhibitors | Fusion inhibitors | Entry inhibitors | Cobicistat | Integrase inhibitors | Hepatitis C virus protease inhibitors |
|------|-------------------------------------------|-----------------------------------------------|------------------------|------------------|-----------------|-------------|--------------------|-------------------------------------|
| 2007 | 90.7                                      | 50.8                                          | 50.8                   | 2.2              | 0.3             | 0.0         | 2.0                | 0.0                                 |
| 2008 | 91.3                                      | 54.1                                          | 48.3                   | 1.2              | 1.0             | 0.0         | 7.6                | 0.0                                 |
| 2009 | 91.1                                      | 55.1                                          | 45.6                   | 0.5              | 1.2             | 0.0         | 11.1               | 0.0                                 |
| 2010 | 90.9                                      | 55.6                                          | 42.6                   | 0.3              | 1.4             | 0.0         | 13.8               | 0.0                                 |
| 2011 | 90.6                                      | 56.3                                          | 40.3                   | 0.2              | 1.7             | 0.0         | 16.2               | 0.0                                 |
| 2012 | 90.9                                      | 57.7                                          | 37.0                   | 0.2              | 1.7             | 0.0         | 18.4               | 0.0                                 |
| 2013 | 91.8                                      | 57.1                                          | 34.5                   | 0.2              | 2.0             | 1.2         | 22.9               | 0.0                                 |
| 2014 | 91.7                                      | 54.0                                          | 30.8                   | 0.2              | 2.0             | 5.0         | 29.5               | 0.0                                 |
| 2015 | 91.9                                      | 48.5                                          | 25.5                   | 0.2              | 1.8             | 9.6         | 36.2               | 0.0                                 |

Other medications with potential contraindications with statins

- Nefazodone: 0.1%
- Gemfibrozil: 2.9%
- Amiodarone: 0.1%
- Calcium channel blockers: 7.0%
- Antifungal medications: 7.6%
- Antibiotics: 4.8%
- Hepatitis C virus protease inhibitors: 0.0%

### Table 3. Percentage of Beneficiaries With HIV Taking Statin Therapy During the Assessment Year, Overall and by Statin Type

| Year | Any statin | Atorvastatin | Fluvastatin | Lovastatin | Pitavastatin | Pravastatin | Rosuvastatin | Simvastatin |
|------|------------|--------------|-------------|------------|--------------|-------------|--------------|------------|
| 2007 | 24.6       | 13.1         | 0.2         | 0.6        | 0.0          | 5.0         | 4.0          | 3.4        |
| 2008 | 25.3       | 12.6         | 0.2         | 0.5        | 0.0          | 5.6         | 4.4          | 3.6        |
| 2009 | 25.6       | 11.9         | 0.2         | 0.4        | 0.0          | 5.6         | 4.9          | 3.9        |
| 2010 | 25.4       | 10.8         | 0.1         | 0.4        | 0.0          | 6.4         | 5.1          | 4.1        |
| 2011 | 25.5       | 10.3         | 0.1         | 0.4        | 0.1          | 6.8         | 5.6          | 4.0        |
| 2012 | 26.0       | 11.2         | 0.1         | 0.3        | 0.1          | 6.6         | 5.9          | 3.3        |
| 2013 | 26.4       | 12.5         | 0.1         | 0.3        | 0.2          | 6.3         | 5.6          | 2.9        |
| 2014 | 25.5       | 12.4         | 0.1         | 0.3        | 0.2          | 5.9         | 5.4          | 2.4        |
| 2015 | 24.7       | 12.9         | 0.1         | 0.3        | 0.2          | 5.4         | 4.8          | 2.1        |

Numbers in the table represent percentages over the total number of beneficiaries. ART indicates antiretroviral therapy.

DOI: 10.1161/JAHA.118.010345

Journal of the American Heart Association
Table 4. Use of ART and Other Medications With Potential Contraindications With Statins Among Beneficiaries With HIV Taking Statin Therapy

| ART                                | 2007 (n=2445) | 2008 (n=2958) | 2009 (n=5084) | 2010 (n=5346) | 2011 (n=6312) | 2012 (n=7318) | 2013 (n=6570) | 2014 (n=6177) | 2015 (n=5386) |
|------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Nucleoside reverse transcriptase inhibitors | 91.8         | 92.2         | 90.8         | 90.5         | 90.4         | 90.1         | 90.4         | 90.4         | 90.7         |
| Non-nucleoside reverse transcriptase inhibitors | 54.4         | 58.1         | 58.0         | 58.3         | 59.0         | 60.0         | 58.8         | 56.3         | 52.2         |
| HIV protease inhibitors            | 54.6         | 51.8         | 48.6         | 46.0         | 44.3         | 40.6         | 38.9         | 36.0         | 32.0         |
| Fusion inhibitors                  | 2.9          | 1.5          | 0.7          | 0.4          | 0.3          | 0.2          | 0.2          | 0.2          | 0.1          |
| Entry inhibitors                   | 0.3          | 1.4          | 1.7          | 1.7          | 2.3          | 2.4          | 2.6          | 2.3          | 2.3          |
| Cobicistat                         | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.8          | 3.8          | 6.7          | 12.3         |
| Integrase inhibitors               | 2.9          | 9.5          | 13.9         | 17.0         | 19.7         | 22.1         | 26.4         | 32.3         | 39.4         |

Other medications with potential contraindications with statins

| Nelfinavir                        | 0.3          | 0.2          | 0.1          | 0.2          | 0.1          | 0.1          | 0.1          | 0.1          | 0.0          |
| Gemfibrozil                       | 5.3          | 5.2          | 4.5          | 3.8          | 3.2          | 3.1          | 2.6          | 2.4          | 2.4          |
| Amiodarone                        | 0.2          | 0.1          | 0.3          | 0.3          | 0.4          | 0.3          | 0.3          | 0.3          | 0.3          |
| Calcium channel blockers          | 11.2         | 11.8         | 11.3         | 11.9         | 12.0         | 12.6         | 13.0         | 15.1         | 15.9         |
| Antifungal medications            | 6.1          | 5.7          | 5.2          | 4.5          | 4.5          | 4.5          | 4.0          | 4.0          | 4.0          |
| Antibiotics                       | 4.9          | 3.4          | 4.1          | 2.8          | 3.0          | 2.6          | 2.1          | 2.1          | 2.4          |
| Hepatitis C virus protease inhibitors | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.1          | 0.0          | 0.1          | 0.0          |

Numbers in the table represent percentages over the total number of beneficiaries taking statin therapy. ART indicates antiretroviral therapy.
were the most commonly used non-ART medications with potential statin contraindications.

Contraindicated Statin Use

Among beneficiaries taking a statin, the percentage taking 1 with a contraindication declined from 16.3% in 2007 to 9.0% in 2014 and 9.8% in 2015 (Figure). The lower use of contraindicated statins in 2015 versus 2007 was primarily the result of decreased use of HIV protease inhibitors, which accounted for 63.9% and 51.0% of all contraindicated statin fills in 2007 and 2015, respectively (Table 5). The higher use of contraindicated statins in 2015 versus 2014 was primarily attributable to cobicistat, which accounted for 20.6% of all contraindicated statin fills in 2015.

Between 2007 and 2010, simvastatin represented about a third of all contraindicated statin fills and this percentage declined to 13.5% in 2015 (Table 6). The proportion of contraindicated statin fills that were associated with fluvastatin also declined between 2007 and 2015, while those for

Table 5. Contraindicated Statin Fills in the Assessment Year Attributed to ART and Other Medications With Potential Contraindications With Statins

|          | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 |
|----------|------|------|------|------|------|------|------|------|------|
| Contraindicated statin fills, n | 1736 | 1944 | 3465 | 3255 | 3510 | 3666 | 2940 | 2573 | 2440 |
| ART      |      |      |      |      |      |      |      |      |      |
| HIV protease inhibitors | 63.9 | 60.2 | 63.2 | 60.6 | 62.5 | 63.4 | 59.2 | 57.2 | 51.0 |
| Cobicistat | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  | 0.4  | 6.5  | 13.1 | 20.6 |
| Other medications with potential contraindications with statins | | | | | | | | | |
| Nefazodone | 0.1  | 0.1  | 0.0  | 0.1  | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  |
| Gemfibrozil | 28.7 | 33.2 | 28.1 | 29.8 | 27.8 | 28.9 | 28.8 | 26.0 | 22.6 |
| Amiodarone | 0.0  | 0.0  | 0.4  | 0.2  | 0.0  | 0.2  | 0.2  | 0.0  | 0.0  |
| Calcium channel blockers | 4.2  | 3.9  | 6.1  | 7.5  | 7.8  | 5.8  | 3.8  | 2.6  | 4.5  |
| Antifungal medications | 0.9  | 0.3  | 0.3  | 0.4  | 0.3  | 0.2  | 0.2  | 0.1  | 0.0  |
| Antibiotics | 2.2  | 2.2  | 1.9  | 1.5  | 1.5  | 1.1  | 1.4  | 1.1  | 1.3  |
| Hepatitis C virus protease inhibitors | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  |

With the exception of the first row (contraindicated statin fills, n), the numbers in the table represent column percentages over the total number of contraindicated statin fills (ie, beneficiaries may have multiple contraindicated statin fills in the assessment year). ART indicates antiretroviral therapy.

DOI: 10.1161/JAHA.118.010345
Table 6. Distribution of Contraindicated Statin Fills in the Assessment Year by Statin Type and Dosage

| Statin Type | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  | 2013  | 2014  | 2015  |
|-------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Contraindicated statin fills, n | 1736  | 1944  | 3465  | 3255  | 3510  | 3666  | 2940  | 2573  | 2440  |
| Atorvastatin |       |       |       |       |       |       |       |       |       |
| Any dose     | 37.3  | 40.2  | 40.4  | 37.4  | 39.1  | 41.9  | 52.5  | 56.7  | 58.0  |
| 10 mg        | 3.9   | 4.6   | 3.7   | 2.7   | 3.3   | 3.4   | 3.9   | 2.5   | 2.7   |
| 20 mg        | 5.9   | 6.1   | 4.1   | 3.9   | 3.2   | 2.8   | 5.6   | 5.8   | 5.0   |
| 40 mg        | 21.4  | 24.7  | 26.1  | 21.9  | 21.7  | 26.1  | 31.8  | 39.1  | 40.0  |
| 80 mg        | 6.1   | 4.8   | 6.5   | 8.9   | 10.9  | 9.6   | 11.3  | 9.4   | 10.3  |
| Fluvastatin  |       |       |       |       |       |       |       |       |       |
| Any dose     | 1.2   | 0.7   | 0.4   | 0.2   | 0.1   | 0.2   | 0.0   | 0.2   | 0.2   |
| 20 mg        | 0.7   | 0.6   | 0.3   | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   |
| 80 mg        | 0.5   | 0.2   | 0.1   | 0.2   | 0.1   | 0.2   | 0.0   | 0.2   | 0.2   |
| Lovastatin   |       |       |       |       |       |       |       |       |       |
| Any dose     | 2.8   | 2.1   | 2.5   | 1.2   | 2.3   | 1.5   | 2.4   | 2.3   | 2.3   |
| 10 mg        | 0.0   | 0.1   | 0.0   | 0.1   | 0.1   | 0.5   | 0.8   | 0.7   |       |
| 20 mg        | 2.0   | 1.1   | 1.6   | 0.3   | 0.7   | 0.5   | 1.1   | 1.1   | 1.3   |
| 40 mg        | 0.8   | 0.8   | 0.8   | 0.8   | 1.5   | 0.9   | 0.9   | 0.5   | 0.3   |
| Pitavastatin |       |       |       |       |       |       |       |       |       |
| Any dose     | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 0.2   | 0.3   | 0.3   | 0.7   |
| 1 mg         | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 0.1   | 0.1   | 0.0   | 0.0   |
| 2 mg         | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 0.1   | 0.3   | 0.2   |
| 4 mg         | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 0.1   | 0.1   | 0.0   | 0.5   |
| Pravastatin  |       |       |       |       |       |       |       |       |       |
| Any dose     | 8.2   | 9.8   | 8.7   | 8.7   | 9.3   | 9.8   | 8.8   | 6.8   | 5.2   |
| 10 mg        | 0.5   | 0.1   | 0.4   | 0.3   | 1.0   | 1.1   | 0.6   | 0.3   | 0.1   |
| 20 mg        | 1.3   | 2.5   | 2.1   | 1.8   | 2.7   | 1.7   | 1.9   | 1.9   | 1.5   |
| 40 mg        | 4.7   | 4.8   | 5.0   | 4.9   | 3.4   | 4.3   | 4.3   | 3.0   | 2.3   |
| 80 mg        | 1.7   | 2.5   | 1.3   | 1.7   | 2.2   | 2.7   | 2.1   | 1.6   | 1.4   |
| Rosuvastatin |       |       |       |       |       |       |       |       |       |
| Any dose     | 17.1  | 17.3  | 16.9  | 21.0  | 20.5  | 24.8  | 20.3  | 18.6  | 20.0  |
| 5 mg         | 0.2   | 0.4   | 0.6   | 0.9   | 0.9   | 1.0   | 0.8   | 1.3   | 1.5   |
| 10 mg        | 0.9   | 1.0   | 1.2   | 1.5   | 1.4   | 1.9   | 2.2   | 1.5   | 1.8   |
| 20 mg        | 12.8  | 11.9  | 11.6  | 14.2  | 14.4  | 15.9  | 11.9  | 11.0  | 11.1  |
| 40 mg        | 3.2   | 4.0   | 3.5   | 4.5   | 3.9   | 6.1   | 5.5   | 4.9   | 5.7   |
| Simvastatin  |       |       |       |       |       |       |       |       |       |
| Any dose     | 33.5  | 29.9  | 31.1  | 31.4  | 28.6  | 21.6  | 15.7  | 15.0  | 13.5  |
| 5 mg         | 0.2   | 0.5   | 0.3   | 0.6   | 0.3   | 0.2   | 0.1   | 0.2   | 0.1   |
| 10 mg        | 3.8   | 2.4   | 1.3   | 2.0   | 2.0   | 0.8   | 1.2   | 1.2   | 1.2   |
| 20 mg        | 13.8  | 11.5  | 10.9  | 9.4   | 8.5   | 6.8   | 6.5   | 5.9   | 3.6   |
| 40 mg        | 12.2  | 10.3  | 12.1  | 12.1  | 13.3  | 12.2  | 7.0   | 7.5   | 8.2   |
| 80 mg        | 3.5   | 5.3   | 6.5   | 7.3   | 4.5   | 4.5   | 1.6   | 0.9   | 0.2   |

With the exception of the first row (contraindicated statin fills, n), the numbers in the table represent column percentages over the total number of contraindicated statin fills (ie, beneficiaries may have multiple contraindicated statin fills in the assessment year).

DOI: 10.1161/JAHA.118.010345
Statin Use Among HIV Patients  Rosenson et al

Factors Associated With Contraindicated Statin Use Among Beneficiaries With HIV Taking Statin Therapy

Among beneficiaries with HIV taking statin therapy, contraindications declined between 2007 and 2015, and this association remained statistically significant after multivariable adjustment (Table 7). Older age, male sex, living in the West, North Central, and South versus the Northeast region of the United States, and having a history of CHD, hypertension, diabetes mellitus, and chronic kidney disease were associated with an increased risk for taking a contraindicated statin among beneficiaries with HIV taking statin therapy in unadjusted analyses. With the exception of chronic kidney disease, these factors remained associated with an increased risk for contraindicated statin use after multivariable adjustment.

Discussion

In the current analysis, about 25% of beneficiaries living with HIV were taking a statin and this percentage did not change substantially between 2007 and 2015. The proportion of patients with HIV taking contraindicated statins declined between 2007 and 2014, primarily as the result of the lower use of protease inhibitors. This decline was partially counteracted by the increased use of cobicistat after 2012. As a consequence of the increased use of cobicistat, the proportion of HIV beneficiaries taking contraindicated statins did not continue to decrease through 2015. Factors associated with contraindicated statin use included older age, male sex, living in the North Central, South, and West versus the Northeast region of the United States, and having a history of CHD, hypertension, and diabetes mellitus.

Statins are considered the first-line therapy to lower CVD risk in HIV-infected adults by the National Lipid Association because of their cholesterol-lowering and anti-inflammatory properties. Previous studies suggest that the use of statin therapy is low among HIV-infected adults. The current analysis expands on prior studies by showing that the use of statin therapy has not increased between 2007 and 2015 among beneficiaries with HIV. This finding is concerning as factors associated with a higher CVD risk, including older age, history of CHD, diabetes mellitus, and chronic kidney disease have increased among beneficiaries with HIV over this time period. These results highlight the need for increasing the appropriate use of statins among patients with HIV. Additionally, studies are needed to identify the barriers preventing statin use among people living with HIV.

Table 7. Risk Ratios (95% Confidence Intervals) for a Contraindicated Statin Use During the Assessment Period Associated With Calendar Year and Beneficiary Characteristics Among Beneficiaries With HIV Taking Statin Therapy

| Region       | Beneficiaries With HIV Taking Statin Therapy (n=47,596) | Unadjusted | Multivariable-Adjusted |
|--------------|--------------------------------------------------------|------------|------------------------|
| Age          |                                                        |            |                        |
| <50 y        | 1 (reference)                                         | 1 (reference) |                        |
| 50 to 59 y   | 1.24 (1.13, 1.35)                                     | 1.23 (1.12, 1.35) |
| ≥60 y        | 1.23 (1.10, 1.37)                                     | 1.18 (1.04, 1.33) |
| Male         | 1.30 (1.13, 1.49)                                     | 1.26 (1.10, 1.45) |
| Year         |                                                        |            |                        |
| 2007         | 1 (reference)                                         | 1 (reference) |                        |
| 2008         | 0.94 (0.87, 1.03)                                     | 0.92 (0.85, 1.01) |
| 2009         | 0.89 (0.81, 0.98)                                     | 0.89 (0.81, 0.98) |
| 2010         | 0.83 (0.75, 0.92)                                     | 0.82 (0.74, 0.91) |
| 2011         | 0.73 (0.66, 0.82)                                     | 0.71 (0.64, 0.79) |
| 2012         | 0.62 (0.56, 0.69)                                     | 0.60 (0.54, 0.67) |
| 2013         | 0.60 (0.54, 0.67)                                     | 0.57 (0.51, 0.64) |
| 2014         | 0.55 (0.49, 0.62)                                     | 0.53 (0.47, 0.59) |
| 2015         | 0.60 (0.54, 0.68)                                     | 0.57 (0.50, 0.64) |
| Region       |                                                        |            |                        |
| Northeast    | 1.28 (1.10, 1.50)                                     | 1.21 (1.03, 1.41) |
| North Central| 1.22 (1.07, 1.39)                                     | 1.18 (1.04, 1.35) |
| South        | 1.36 (1.18, 1.56)                                     | 1.29 (1.12, 1.48) |
| West         | 1.04 (0.67, 1.61)                                     | 1.04 (0.67, 1.60) |
| Unknown      | 1.49 (1.34, 1.65)                                     | 1.34 (1.20, 1.50) |
| Comorbidities|                                                        |            |                        |
| Coronary heart disease | 1.28 (1.18, 1.40)                     | 1.16 (1.06, 1.27) |
| Hypertension | 1.43 (1.29, 1.58)                                     | 1.38 (1.24, 1.54) |
| Diabetes mellitus | 1.13 (0.88, 1.45)               | 1.01 (0.78, 1.30) |
| Stroke       | 1.28 (1.14, 1.44)                                     | 1.12 (0.99, 1.27) |
| Liver disease | 0.88 (0.70, 1.10)                                     | 0.82 (0.66, 1.03) |

The multivariable adjusted model includes adjustment for all variables in the table simultaneously.

In the current analysis, the use of contraindicated statins among beneficiaries with HIV declined between 2007 and 2014. This decline was mainly the result of the lower use of protease inhibitors. Results from the current analysis also suggest that cobicistat, a pharmacokinetic booster/enhancer, has counteracted some of the decline in contraindicated statin use. Cobicistat is a potent inhibitor of the cytochrome P-450 3A4 (CYP3A4) and increases the concentration of...
statins metabolized through this enzyme system.\textsuperscript{19,20} Cobicistat may also increase the serum concentration of statins by inhibiting the permeability glycoprotein, the breast cancer resistance protein, and the organic anion-transporting polypeptides 1B1 and 1B3.\textsuperscript{19,20} Cobicistat was initially approved by the Food and Drug Administration in a fixed-dose combination with elvitegravir, emtricitabine, and tenofovir disoproxil in August 2012.\textsuperscript{21} After its approval, the use of cobicistat increased substantially among adults with HIV.\textsuperscript{10} In the current analysis, the use of contraindicated statins attributable to taking cobicistat increased substantially between 2012 and 2015. This finding suggests a lack of awareness of contraindications for statin therapy associated with cobicistat. Increasing physicians’ awareness and implementing electronic prescription systems with drug-drug interaction checks may reduce the contraindicated use of statins attributed to cobicistat among HIV patients.\textsuperscript{22,23}

Patients with HIV taking cobicistat who initiate statin therapy should be prescribed atorvastatin or rosuvastatin at the lowest dosages and these medications should be titrated with close monitoring for adverse reactions.\textsuperscript{8,24}

Non-ART therapies commonly prescribed in adults with HIV also contribute to the use of contraindicated statins. In the current analysis, gemfibrozil accounted for 22.6\% of contraindicated statin use in 2015. Elevated triglycerides levels are common among HIV patients, particularly in those taking protease inhibitors.\textsuperscript{25} In HIV patients requiring triglyceride-lowering therapy, fenofibrate and omega-3 fatty acids should be preferred over gemfibrozil given their lower risk for rhabdomyolysis when combined with statins.\textsuperscript{26,27} In the current analysis, the use of calcium channel blockers increased between 2007 and 2015, presumably because of the higher prevalence of hypertension in more recent years. In 2015, calcium channel blockers accounted for 4.5\% of contraindicated statin use. Among HIV patients with hypertension taking statins, the use of antihypertensive medication classes other than calcium channel blockers should be considered. The 2017 American College of Cardiology/American Heart Association blood pressure guideline recommends thiazide diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers in addition to calcium channel blockers for adults initiating antihypertensive medication.\textsuperscript{28} Future surveillance on the use of calcium channel blockers and statins among HIV patients is warranted as this population is aging.

Simvastatin and lovastatin should be avoided in HIV-infected adults as these medications are contraindicated with several ARTs including protease inhibitors.\textsuperscript{9,11,13} Use of atorvastatin, rosuvastatin, or pitavastatin is preferable in HIV patients, although dosing adjustments may be required.\textsuperscript{9,13} In the current analysis, there was a decline in the proportion of contraindicated statin attributable to simvastatin, particularly after 2010. Several factors could have contributed to this decline in the use of simvastatin, including increasing awareness about the contraindication with ART, increased concerns about adverse muscle events associated with this medication,\textsuperscript{29,30} and the availability of low-cost atorvastatin after becoming generic in 2011.\textsuperscript{31} In 2015, 58.0\% and 20.0\% of contraindicated statin use was attributable to atorvastatin and rosuvastatin, respectively. These results suggest a lack of awareness on the need for dosing adjustment when using atorvastatin and rosuvastatin in people with HIV.

The use of contraindicated statins was higher in subgroups with high CVD risk, including older patients, men, and those with CHD, hypertension, or diabetes mellitus. This finding may be explained by the use of high-intensity statin dosages in these groups. The use of contraindicated statins was also higher in beneficiaries with HIV living in the South and West versus the Northeast US region. Given the high proportion of HIV-patients living in the South and West regions of the United States,\textsuperscript{32} increased awareness of contraindicated statins by healthcare professionals who care for HIV patients in these regions is warranted.

We analyzed trends and factors associated with contraindicated use of statins as this increases the risk for adverse events associated with this medication.\textsuperscript{9,13} Some medications commonly used among HIV patients may reduce the efficacy of statin therapy.\textsuperscript{9} Non-nucleoside reverse transcriptase inhibitors may reduce serum concentrations of statins metabolized through the CYP3A4 enzyme system.\textsuperscript{9} Because non-nucleoside reverse transcriptase inhibitors do not increase the risk for statin-related adverse events, these medications were not considered a contraindication in the current analysis. However, clinicians should be aware of possible drug-drug interactions when prescribing statins in HIV-patients taking non-nucleoside reverse transcriptase inhibitors.\textsuperscript{8}

Strengths of the current study include the availability of data on ART and statin use in a large cohort of HIV patients from all regions of the United States. The pharmacy data we used included medications and dosages. The current study has several known and potential limitations. Misclassification of the use of statins, ART, and other medications with contraindications with statins is possible given that we relied on pharmacy fill data. These data indicate that beneficiaries filled a prescription but not whether they took it. Also, using administrative claims data may result in misclassification of baseline characteristics and HIV infection status if diagnosis codes for these conditions are not used or incorrectly used. We lacked data on estimated glomerular filtration rate, which prevented us from determining additional contraindications with specific statin doses resulting from renal impairment. Also, we did not have data on socioeconomic status and race/ethnicity. These data are not available in Marketscan.
Statin Use Among HIV Patients

Rosenson et al

References

Amgen, Astra Zeneca, Medicines Company and Regeneron, Disclosures

Acknowledgments

Sources of Funding

Disclosures

References

3. Croxford S, Kitching A, Desai S, Kall M, Edelman M, Skingsley A, Burns F, Copas A, Brown AE, Sullivan AK, Delpech V, Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Public Health. 2017;2:e35–e46.

4. Boccarda F, Lang S, Meuleman C, Ederthy S, Mary-Krause M, Costagliola D, Capeau J, Cohen A. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol. 2013;61:1151–1237.

5. Vachat A, McCutcheon K, Tsabedze N, Zachariah D, Manga P. HIV and ischemic heart disease. J Am Coll Cardiol. 2017;69:73–82.

6. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollinico C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;360:1267–1278.

7. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hoehman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–S45.

8. Wiggins BS, Lamperecht DG Jr, Page RL II, Saseen J. Recommendations for managing drug-drug interactions with statins and HIV medications. Am J Cardi-Carevasc Drugs. 2017;17:375–389.

9. Wiggins BS, Saseen J, Page RL II, Reed BN, Sneed K, Kostis JB, Lanfear D, Virani S, Morris PB. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association Circulation. 2016;134:e468–e495.

10. Eaton EF, Tamhane A, Davy-Mendez T, Mathews WC, Moore RD, Saag MS, Mugavero MJ. Trends in antiretroviral therapy prescription, adherence and modification: new drugs, more changes, but less failure. AIDS. 2018;32:347–355.

11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living With HIV. Washington, DC: Department of Health and Human Services; 2017. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 28, 2018.

12. Chen W, Qian L, Shi J, Franklin M. Comparing performance between binomial and robust Poisson regression models for estimating risk ratios under model misspecification. BMC Med Res Methodol. 2018;18:63.

13. Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Davgulis M, Ferdinand KG, Vijayaratnakorn K, Deedwania PC, Abeg JAR, Liao KP, McMenamy JM, Ross JL, Braun LT,合约 MK, Bays HE, Brown WV, Underberg JA. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9:5;S1–122.e121.

14. Freiberg MS, Leaf DA, Goetz JL, Goetz MB, Oursler KK, Gibert CL, Rodriguez-Bansbach MC, Butt AA, Justice AC. The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication. J Gen Intern Med. 2009;24:334–340.

15. Todd JV, Cole SR, Wohl DA, Simpson RJ Jr, Jonsson Funk M, Brookhart MA, Cocohoba J, Merenstein D, Sharma A, Lazar J, Milan M, Cohen M, Gange S, Lewis TT, Burkholder G, Adimora AA. Underutilization of statins when indicated among community-dwelling veterans living with HIV that was compared with the general population: an analysis of a national observational cohort. REasons for Geographic and Racial Differences in Stroke (REGARDS). J Am Heart J. 2017;2:e46–e495.

16. Mondesir FL, Brown TM, Muntner P, Duram RW, Carson AP, Safford MM, Levitan EB. Diabetes, diabetes severity, and coronary heart disease risk equivalence: REAsons for Geographic and Racial Differences in Stroke (REGARDS). Am Heart J. 2016;181:43–51.
19. Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. *Clin Pharmacokinet*. 2013;52:815–831.

20. Deeks ED. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. *Drugs*. 2014;74:195–206.

21. Belavic JM. Drug updates and approvals: 2012 in review. *Nurse Pract*. 2013;38:24–42.

22. Ammenwerth E, Schnell-Inderst P, Machan C, Siebert U. The effect of electronic prescribing on medication errors and adverse drug events: a systematic review. *J Am Med Inform Assoc*. 2008;15:585–600.

23. Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. *Arch Intern Med*. 2003;163:1409–1416.

24. Custodio JM, Wang H, Hao J, Lepist EI, Andrews J, Ling KH, Cheng A, Kearney BP, Ramanathan S. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosvastatin. *J Clin Pharmacol*. 2014;54:649–656.

25. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. *J Antimicrob Chemother*. 2004;53:10–14.

26. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. *Am J Cardiol*. 2007;99:3c–18c.

27. Oliveira JM, Rondo PH. Omega-3 fatty acids and hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: systematic review and meta-analysis. *HIV Clin Trials*. 2011;12:268–274.

28. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71:e13–e115.

29. US Food and Drug Administration. FDA Drug Safety Communication: New Restrictions, Contraindications, and Dose Limitations for Zocor (Simvastatin) to Reduce the Risk of Muscle Injury. Silver Springs, MD: US Department of Health & Human Services; 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm. Accessed April 11, 2016.

30. Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. *Intern Med*. 2011;50:845–853.

31. Luo J, Seeger JD, Donneyong M, Gagne JJ, Avorn J, Kesselheim AS. Effect of generic competition on atorvastatin prescribing and patients’ out-of-pocket spending. *JAMA Intern Med*. 2016;176:1317–1323.

32. Centers for Disease Control Prevention. *HIV Surveillance Report*, 2016; Vol. 28. Atlanta, GA: Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, US Department of Health and Human Services; 2017. Available at: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed February 28, 2018.
SUPPLEMENTAL MATERIAL
Table S1. Cascade of beneficiaries with HIV included in the current analysis.

| Criteria                                                                 | 2007          | 2008          | 2009          | 2010          | 2011          | 2012          | 2013          | 2014          | 2015          |
|--------------------------------------------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| Had medical coverage in the assessment and baseline years                | 18,796,150    | 18,719,527    | 27,745,990    | 27,705,972    | 29,198,060    | 32,689,682    | 25,426,912    | 24,692,985    | 17,247,365    |
| Had pharmacy coverage in the assessment and baseline years              | 13,910,859    | 15,162,188    | 21,150,244    | 22,253,050    | 23,467,368    | 26,232,014    | 21,177,823    | 19,752,611    | 16,301,118    |
| Alive on December 31 of the assessment year                             | 13,903,998    | 15,152,507    | 21,135,925    | 22,236,418    | 23,447,148    | 26,212,571    | 21,161,279    | 19,738,038    | 16,290,590    |
| Lived in the United States in the assessment and baseline years         | 13,903,661    | 15,152,374    | 21,135,125    | 22,232,988    | 23,443,764    | 26,212,386    | 21,161,188    | 19,737,964    | 16,290,370    |
| Age ≥19 years on January 1 of the assessment year                       | 10,865,088    | 11,839,144    | 6,380,286     | 17,235,998    | 18,333,731    | 20,587,102    | 16,703,634    | 15,545,306    | 12,850,818    |
| Had ≥1 HIV inpatient diagnosis code or ≥2 pharmacy fills for ART in the baseline year | 10,135        | 11,939        | 20,218        | 21,390        | 25,113        | 28,443        | 25,113        | 24,420        | 21,985        |
| Had ≥1 pharmacy fill for ART in the baseline year                       | 9,928         | 11,713        | 19,868        | 21,084        | 24,781        | 28,104        | 24,892        | 24,225        | 21,825        |

ART: antiretroviral therapy; HIV: human immunodeficiency virus.
| Characteristics           | Definition                                                                 |
|--------------------------|-----------------------------------------------------------------------------|
| Coronary heart disease   | Any of the following:                                                        |
|                          | • ≥1 hospitalization or physician evaluation and management visit with a    |
|                          |   diagnosis code of MI (ICD-9-CM diagnosis code of 410.xx or 412.xx) in any |
|                          |   discharge diagnosis position                                              |
|                          | • ≥1 hospitalization or physician visit with a procedure code for          |
|                          |   revascularization (ICD-9-CM procedure codes 00.66, 36.0, 36.01-36.19,    |
|                          |   36.2, ICD-9-CM diagnosis codes V45.81 or V45.82, or CPT codes 33510-      |
|                          |   33519, 33521-33523, 33530, 33533-33536, 92980-92982, 92984, 92995, 92996)  |
|                          | • ≥1 inpatient or physician evaluation and management visit with another    |
|                          |   CHD-related code (ICD-9-CM code of 411.xx, 413.xx, or 414.xx)             |
| Hypertension             | Any of the following:                                                        |
|                          | • ≥1 hospitalization with a discharge diagnosis code of 401.xx in any      |
|                          |   discharge diagnosis position                                              |
|                          | • ≥2 physician evaluation and management visits with an ICD-9-CM diagnosis |
|                          |   code of 401.xx in any position at least 7 days apart                      |
| History of diabetes      | Any of the following:                                                        |
|                          | • ≥1 hospitalization with a discharge diagnosis code of diabetes (ICD-9-CM |
|                          |   diagnosis codes 250.xx, 357.2, 362.0x, or 366.41) in any discharge       |
|                          |   diagnosis position                                                        |
|                          | • ≥2 physician evaluation and management visits with a diagnosis code of    |
|                          |   diabetes (ICD-9-CM diagnosis codes 250.xx, 357.2, 362.0x, or 366.41) in  |
|                          |   any position occurring at least 7 days apart                              |
|                          | • ≥1 pharmacy for an oral hypoglycemic medication or insulin                |
| History of stroke        | Any of the following:                                                        |
|                          | • ≥1 hospitalization with a discharge diagnosis code of stroke (ICD-9-CM   |
|                          |   discharge diagnosis code of 430.xx, 431.xx, 433.x1, 434.x1 or 436.x) in  |
|                          |   any discharge diagnosis position                                          |
|                          | • ≥1 physician evaluation and management visit with a diagnosis code of    |
|                          |   stroke (ICD-9-CM discharge diagnosis code of 430.xx, 431.xx, 433.x1, 434.| |
|                          |   x1 or 436.x) in any position                                              |
| Chronic kidney disease   | Any of the following:                                                        |
|                          | • ≥1 hospitalization with a discharge diagnosis code of chronic kidney     |
|                          |   disease (ICD-9-CM diagnosis code of 016.0x, 095.4, 189.0, 189.9, 223.0,  |
|                          |   236.91, 250.4x, 271.4, 274.1x, 283.11, 403.x1, 403.x0, 404.x2, 404.x3,  |
|                          |   404.x0, 404.x1, 440.1, 442.1, 447.3, 572.4, 580–588, 591, 642.1x, 646.2x,  |
|                          |   753.12–753.17, 753.19, 753.2x, or 794.4) in any discharge diagnosis      |
|                          |   position                                                                  |
|                          | • ≥1 physician evaluation and management visit with a diagnosis code of    |
|                          |   chronic kidney disease (ICD-9-CM diagnosis code of 016.0x, 095.4, 189.0,  |
|                          |   189.9, 223.0, 236.91, 250.4x, 271.4, 274.1x, 283.11, 403.x1, 403.x0, 404.| |
|                          |   x2, 404.x3, 404.x0, 404.x1, 440.1, 442.1, 447.3, 572.4, 580–588, 591, 642.| |
|                          |   1x, 646.2x, 753.12–753.17, 753.19, 753.2x, or 794.4) in any position     |
| Liver disease            | Any of the following:                                                        |
|                          | • ≥1 hospitalization or physician evaluation and management visit with a   |
|                          |   diagnosis code of MI (ICD-9-CM diagnosis code of 410.xx or 412.xx) in any|
|                          |   discharge diagnosis position                                              |
|                          | • ≥1 hospitalization or physician visit with a procedure code for          |
|                          |   revascularization (ICD-9-CM procedure codes 00.66, 36.0, 36.01-36.19,    |
|                          |   36.2, ICD-9-CM diagnosis codes V45.81 or V45.82, or CPT codes 33510-      |
|                          |   33519, 33521-33523, 33530, 33533-33536, 92980-92982, 92984, 92995, 92996)  |
|                          | • ≥1 inpatient or physician evaluation and management visit with another  |
|                          |   CHD-related code (ICD-9-CM code of 411.xx, 413.xx, or 414.xx)             |

Table S2. Definitions for patient characteristics.
| Characteristics                                                                 | Definition                                                                                                                                                                                                 |
|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • ≥1 hospitalization with a discharge diagnosis code of liver disease (ICD-9-CM diagnosis codes 070.0, 070.1, 070.20–070.23, 070.30–070.33, 070.41–070.44, 070.49, 070.51–070.54, 070.59, 070.6, 070.70, 070.71, 070.9, 275.0x, 275.1, 456.0, 456.1, 456.20, 456.21, 571.0–571.3, 571.40–571.42, 571.49, 571.5, 571.6, 571.8, 571.9, 572.2–572.4, 572.8, 573.3, 573.5, 573.8, 576.1, 576.8, 782.4, E947.9, V02.60, V02.61, V02.62, V02.69, or V42.7) in any discharge diagnosis position |
| • ≥2 physician evaluation and management visits with a diagnosis code of liver disease (ICD-9-CM diagnosis codes 070.0, 070.1, 070.20–070.23, 070.30–070.33, 070.41–070.44, 070.49, 070.51–070.54, 070.59, 070.6, 070.70, 070.71, 070.9, 275.0x, 275.1, 456.0, 456.1, 456.20, 456.21, 571.0–571.3, 571.40–571.42, 571.49, 571.5, 571.6, 571.8, 571.9, 572.2–572.4, 572.8, 573.3, 573.5, 573.8, 576.1, 576.8, 782.4, E947.9, V02.60, V02.61, V02.62, V02.69, or V42.7) in any position occurring on separate days |

CPT: Current Procedure Terminology; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification; MI: myocardial infarction.
Physician evaluation and management visits include ambulatory visit, emergency department, inpatient face-to-face and nursing home.
| Contraindicated medication group | Contraindicated medication | Contraindicated statin dose |
|---------------------------------|---------------------------|---------------------------|
| Nefazodone                      | Nefazodone                | Lovastatin any dose       |
|                                 |                           | Simvastatin any dose      |
| Gemfibrozil                     | Gemfibrozil               | Atorvastatin any dose     |
|                                 |                           | Fluvastatin any dose      |
|                                 |                           | Lovastatin any dose       |
|                                 |                           | Pitavastatin any dose     |
|                                 |                           | Pravastatin any dose      |
|                                 |                           | Rosuvastatin any dose     |
|                                 |                           | Simvastatin any dose      |
| Amiodarone                      | Amiodarone                | Lovastatin >40 mg daily   |
|                                 |                           | Simvastatin >20 mg daily  |
| Calcium channel blockers        | Amlodipine                | Simvastatin >20 mg daily  |
|                                 |                           | Lovastatin >20 mg daily   |
|                                 | Diltiazem                  | Simvastatin >10 mg daily  |
|                                 | Verapamil                  | Lovastatin >20 mg daily   |
|                                 |                            | Simvastatin >10 mg daily  |
| Antifungal medications          | Fluconazole               | Fluvastatin > 40 mg daily |
|                                 |                           | Atorvastatin >20 mg daily |
|                                 |                           | Lovastatin any dose       |
|                                 |                           | Simvastatin any dose      |
|                                 | Itraconazole              | Atorvastatin any dose     |
|                                 |                            | Lovastatin any dose       |
|                                 |                            | Simvastatin any dose      |
|                                 |                            | Posaconazole              |
|                                 |                            | Atorvastatin any dose     |
|                                 |                            | Lovastatin any dose       |
|                                 |                            | Simvastatin any dose      |
|                                 |                            | Voriconazole              |
|                                 |                            | Lovastatin any dose       |
|                                 |                            | Simvastatin any dose      |
| Antibiotics                     | Clarithromycin            | Atorvastatin >20 mg daily |
|                                 |                            | Lovastatin any dose       |
|                                 |                            | Simvastatin any dose      |
|                                 |                            | Pravastatin >40 mg daily  |
|                                 |                            | Simvastatin any dose      |
|                                 |                            | Erythromycin              |
|                                 |                            | Lovastatin any dose       |
|                                 |                            | Pitavastatin >1 mg daily  |
|                                 |                            | Simvastatin any dose      |
|                                 |                            | Rifampin                  |
|                                 |                            | Pitavastatin >2 mg daily  |
|                                 |                            | Simvastatin any dose      |
|                                 |                            | Telithromycin             |
|                                 |                            | Atorvastatin >20 mg daily |
|                                 |                            | Lovastatin any dose       |
|                                 |                            | Simvastatin any dose      |
| Hepatitis C virus protease      | Boceprevir                | Atorvastatin >40 mg daily |
| inhibitors                      |                            | Lovastatin any dose       |
|                                 |                            | Simvastatin any dose      |
|                                 |                            | Simeprevir                |
|                                 |                            | Atorvastatin >40 mg daily |
| Telaprevir | Atorvastatin any dose |
|           | Lovastatin any dose   |
|           | Simvastatin any dose  |
| Cobicistat | Atorvastatin any dose (if in combination with atazanavir) |
|           | Atorvastatin >20 mg daily (if in combination with darunavir or elvitegravir) |
|           | Lovastatin any dose   |
|           | Rosuvastatin >10 mg daily (if in combination with atazanavir) |
|           | Rosuvastatin >20 mg daily (if in combination with darunavir) |
|           | Simvastatin any dose  |
| Human immunodeficiency virus protease inhibitors | Atazanavir |
|           | Lovastatin any dose   |
|           | Simvastatin any dose  |
|           | Darunavir             |
|           | Lovastatin any dose   |
|           | Simvastatin any dose  |
|           | Fosamprenavir         |
|           | Atorvastatin >20 mg daily |
|           | Lovastatin any dose   |
|           | Simvastatin any dose  |
|           | Indinavir             |
|           | Lovastatin any dose   |
|           | Simvastatin any dose  |
|           | Nelfinavir            |
|           | Atorvastatin >40 mg daily |
|           | Lovastatin any dose   |
|           | Simvastatin any dose  |
|           | Ritonavir             |
|           | Lovastatin any dose   |
|           | Simvastatin any dose  |
|           | Ritonavir-boosted atazanavir |
|           | Rosuvastatin >10 mg daily |
|           | Ritonavir-boosted darunavir |
|           | Atorvastatin >20 mg daily |
|           | Ritonavir-boosted fosamprenavir |
|           | Atorvastatin >20 mg daily |
|           | Ritonavir-boosted lopinavir |
|           | Rosuvastatin >10 mg daily |
|           | Ritonavir-boosted saquinavir |
|           | Atorvastatin >20 mg daily |
|           | Saquinavir             |
|           | Lovastatin any dose   |
|           | Simvastatin any dose  |
|           | Tipranavir             |
|           | Atorvastatin any dose |
|           | Lovastatin any dose   |
|           | Simvastatin any dose  |
Supplemental References:

1. Kent ST, Safford MM, Zhao H, Levitan EB, Curtis JR, Kilpatrick RD, Kilgore ML, Muntner P. Optimal Use of Available Claims to Identify a Medicare Population Free of Coronary Heart Disease. *Am J Epidemiol*. 2015;182:808-819.

2. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. *Med Care*. 1998;36:8-27.

3. Quan H, Li B, Saunders LD, Parsons GA, Nilsson CI, Alibhai A, Ghali WA. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. *Health Serv Res*. 2008;43:1424-1441.

4. Gandra SR, Lawrence LW, Parasuraman BM, Darin RM, Sherman JJ, Wall JL. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. *J Manag Care Pharm*. 2006;12:546-554.

5. Kumamaru H, Judd SE, Curtis JR, Ramachandran R, Hardy NC, Rhodes JD, Safford MM, Kissela BM, Howard G, Jalbert JJ, Brott TG, Setoguchi S. Validity of claims-based stroke algorithms in contemporary Medicare data: REasons for Geographic And Racial Differences in Stroke (REGARDS) study linked with medicare claims. *Circ Cardiovasc Qual Outcomes*. 2014;7:611-619.

6. Muntner P, Gutierrez OM, Zhao H, Fox CS, Wright NC, Curtis JR, McClellan W, Wang H, Kilgore M, Warnock DG, Bowling CB. Validation study of medicare claims to identify older US adults with CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *Am J Kidney Dis*. 2015;65:249-258.